[PDF] Top 20 DNA vaccine: a promising new approach for chronic hepatitis B therapy.: DNA Vaccine for hepatitis B therapy
Has 10000 "DNA vaccine: a promising new approach for chronic hepatitis B therapy.: DNA Vaccine for hepatitis B therapy" found on our website. Below are the top 20 most common "DNA vaccine: a promising new approach for chronic hepatitis B therapy.: DNA Vaccine for hepatitis B therapy".
DNA vaccine: a promising new approach for chronic hepatitis B therapy.: DNA Vaccine for hepatitis B therapy
... is DNA vaccination pertinent for immunotherapy of HBV-carriers ? DNA vaccination (or genetic vaccination) is an exciting novel immunization approach which was introduced a more than ... Voir le document complet
8
Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification.
... the new version of the CAP/CTM assay is sensitive, specific and reproducible, and that it accurately quantifies HBV DNA in both plasma and serum samples from patients with chronic HBV ...with ... Voir le document complet
11
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
... obstacle for curing chronic HBV ...episomal DNA from hepatocytes through a combination of exogenous treat- ment (presented here) and immune-mediated endogenous ...CRISPR/Cas9-mediated ... Voir le document complet
10
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial
... In a recent study, Rivino et ...NUC therapy discontinuation and performed biomarker analysis to identify immunological biomarkers predictive of safe disconti- ...as a potential marker as these cells ... Voir le document complet
14
Cost-effectiveness model for sofosbuvir in chronic hepatitis C
... 12. Grishchenko M, Grieve RD, Sweeting MJ et al. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol ... Voir le document complet
1
Chronic hepatitis B and HIV care: the key-role of the doctor-patient relationship
... qualitative a été conduite auprès de patients subsahariens ayant une hépatite B chronique ou vivant avec le VIH, et auprès de médecins, entre septembre 2010 et octobre ...L’enquête a été réalisée ... Voir le document complet
10
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.: Mechanism of entecavir resistance
... in the viral population. On the left are indicated the serum sample numbers. Figure 3. Replicative capacity in Huh-7 cells of wt and HBV RT mutants isolated from the patient during lamivudine (A) and entecavir ... Voir le document complet
24
A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus
... A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus David Durantel, Sandra Carrouée-Durantel, Bettina Werle-Lapostolle, Marie-Noë[r] ... Voir le document complet
25
Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients
... of chronic HBV-infection and as human genetic data were not collected in our study, we cannot infer on its particular ...markers for any of the patients in this cohort, regardless of anti-HBs antibody ... Voir le document complet
28
Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa
... confirmed for larger cohorts with more seroclearance ...milestones for qHBsAg is extremely important to consider if it is to be used in resource-limited ...providing a potential explanation of viral- ... Voir le document complet
34
A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae
... few vaccine strategies have been or are in development for ...fact, a 24-valent, purely capsular polysaccharide vaccine (Klebgen Bema) was developed in the 1980s by the Swiss Serum and ... Voir le document complet
10
Liver stiffness diminishes with antiviral response in chronic hepatitis C.: Liver Stiffness Kinetics on HCV Therapy
... For Peer Review Successful therapy with IFN-α or pegylated IFN-α with or without ribavirinhas been shown to be associated with significant histological improvements in studies in which patients underwent ... Voir le document complet
29
Chronic hepatitis C virus infection, a new cardiovascular risk factor?
... be new risk factors associated with certain infectious ...manifestations. Hepatitis C virus (HCV) infection has been associated to a very large number of extrahepatic manifestations in various ... Voir le document complet
20
A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae
... a biological safety ...in a biological safety cabinet for another 24 ...1:4000. For mouse serum titrations, the reciprocal of the last serum dilution that resulted in an optical density at ... Voir le document complet
16
Systematic Review: antiviral therapy of recurrent hepatitis C post liver transplant
... combined therapy with interferon-alfa and ribavirin has ...experienced a sustained virological response (SVR) (30 %) and had significantly fewer liver-related deaths or ...waiting for LT due to HCC, ... Voir le document complet
26
Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design
... of a nucleocapsid containing the viral RNA surrounded by an endo- plasmic reticulum (ER)-derived envelope in which viral E1 and E2 glycoproteins are embedded as heterodimers ( 6 ) (Figure ...). A hallmark ... Voir le document complet
10
Hepatitis B and C virus seroprevalence, Burkina Faso: a cross-sectional study
... but a high degree of regional heterogeneity was observed for HCV; this demonstrates that the assumed epidemiological ho- mogeneity between neighbouring coun- tries used in meta-analyses 8 is not valid at ... Voir le document complet
11
View of Gene Therapy: A Promising Therapeutic Strategy for Malaria
... Gene therapy; Malaria; Gene editing; CRISPR Malaria is a serious illness caused by the Plasmodium parasite, which places approximately ...gene therapy is an emerging field that shows promising ... Voir le document complet
5
The RPGRIP1-deficient dog a promising canine model for gene therapy
... Conclusions: A treatment strategy should consist in initiating gene therapy as early as possible after birth to prevent or delay the loss of rod ...of a therapeutic vector is feasible at 2 months of ... Voir le document complet
14
A Seven-Year Retrospective Study on the Surveillance of Hepatitis B in Laos
... have a limited duration of therapy in HBV therapeutic schemes (if pursued for at least 48 weeks), the absence of drug resistance, and an opportunity to obtain a durable posttreat- ment ... Voir le document complet
13
Sujets connexes